Drug Trial Radar · NCT07173556
A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Sep 2025
Primary completion
Feb 2027
Study completion Oct 2028
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multicenter, Phase Ib/II clinical trial designed to evaluate the safety, tolerability, efficacy, and pharmacokinetic characteristics of QLC1401 tablets in combination with CDK4/6 inhibitors or mTOR inhibitors in patients with ER+/HER2- locally advanced or metastatic breast cancer. The study consists of two stages: a Phase Ib dose-escalation stage and a Phase II dose-expansion stage.
Conditions
- Advanced Breast Cancer
Interventions
QLC1401Drug
CDK4/6 inhibitors: Palbociclib, Abemaciclib, Ribociclib
QLC1401Drug
mTOR inhibitors: Everolimus
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability (Phase Ib)Time frame: Throughout phase Ib (approximately 1 year)
- Recommended phase II dose (RP2D) (Phase Ib)Time frame: Throughout phase Ib (approximately 1 year)
- Objective Response Rate (ORR) (Phase II)Time frame: From time of Informed Consent to confirmed progressive disease (approximately 1 year)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.